Study Title

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Study Details

Description:

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

Sponsor:

University of Alberta

Contacts:

Jonathan Abele, MD (Principal Investigator)

jabele@ualberta.ca

780-407-6907

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468